English | Español

Freedom Foundation of Minnesota
Patient Daily | Mar 30, 2026

Freedom Foundation CEO Meeks on 340B: 'The program has morphed into a veritable ATM for hospitals'

Trending
+ Pharmaceuticals
Patient Daily | Mar 25, 2026

Revolution and Ascendis identified as top buyout targets amid speculation of industry mega-merger
+ Pharmaceuticals
Patient Daily | Mar 25, 2026

Sarepta to seek full FDA approval for Duchenne therapies after failed confirmatory trial
+ Regulatory
Patient Daily | Mar 30, 2026

Freedom Foundation CEO Meeks on 340B: 'The program has morphed into a veritable ATM for hospitals'
+ Pharmaceuticals
Patient Daily | Mar 25, 2026

Lilly reports late-stage diabetes data for triple-G agonist retatrutide